1. Thomasius FE, Baum E, Bernecker P, Böcker W, Kurth A et al. DVO Leitlinie 2017 zur Prophylaxe, Diagnostik und Therapie der Osteoporose bei postmenopausalen Frauen und Männern: Kurzversion. Osteologie 2018, 27 (03) , 154-160
2. Thomasius F, Hadji P. Osteoporose bei hormonablativer Therapie. Osteologie 2018, 1, 27, 14-19
3. Kyvernitakis I, Kann HP, Thomasius F, Hars O, Hadji P. Prevention of breast cancer treatment-induced bone loss in premenopausal women treated with zoledronic acid: Final 5-year results from the randomized, double-blind, placebo-controlled ProBONE II trial. Bone. 2018 Jun 13;114:109-115. doi: 10.1016/j.bone.2018.06.007. [Epub ahead of print]
4. Kyvernitakis I, Kostev K, Nassour T, Thomasius F, Hadji P. The impact of depot medroxyprogesterone acetate on fracture risk: a case-control study from the UK. Osteoporos Int. 2016 Jul 26. [Epub ahead of print]
5. Thomasius F, Keung Nip T, Ivan P. Phase IV randomized preference study in patients eligible for calcium and vitamin D supplementation. Curr Med Res Opin. 2016 Jun 29:1-9. [Epub ahead of print]
6. Hadji P, Kyvernitakis I, Kann PH, Niedhart C, Hofbauer LC, Schwarz H, Kurth AA, Thomasius F, Schulte M, Intorcia M, Psachoulia E, Schmid T. GRAND-4: the German retrospective analysis of long-term persistence in women with osteoporosis treated with bisphosphonates or denosumab. Osteoporos Int. 2016 May 12. [Epub ahead of print]
7. Belavý DL, Armbrecht G, Blenk T, Bock O, Börst H, Kocakaya E, Luhn F, Rantalainen T, Rawer R, Thomasius F, Willnecker J, Felsenberg D..Greater association of peak neuromuscular performance with cortical bone geometry, bone mass and bone strength than bone density: A study in 417 older women. Bone. 2016 Feb;8 3:119-26. doi: 10.1016/j.bone.2015.10.018. Epub 2015 Nov 2
8. Hadji P, Kyvernitakis J, Kann P, Niedhart C, Hofbauer L, Schwarz H, Kurth AA, Thomasius F, Schulte M, Intorcia M, Psachoulia E, Schmid T. Grand-4: The German Retrospective Analysis on Persistence in Women with Osteoporosis Treated with Bisphosphonates or Denosumab. Value Health. 2015 Nov;18(7):A657. doi: 10.1016/j.jval.2015.09.2377. Epub 2015 Oct 20. No abstract available.
9. Farahmand P, Marin F, Hawkins F, Möricke R, Ringe JD, Glüer CC, Papaioannou N, Minisola S, Martínez G, Nolla JM, Niedhart C, Guañabens N, Nuti R, Martín-Mola E, Thomasius F, Peña J, Graeff C, Kapetanos G, Petto H, Gentzel A, Reisinger A, Zysset PK. Early changes in biochemical markers of bone formation during teriparatide therapy correlate with improvements in vertebral strength in men with glucocorticoid-induced osteoporosis. Osteoporos Int. 2013 Dec;24(12):2971-81. doi: 10.1007/s00198-013-2379-5. Epub 2013 Jun 6.
10. Glüer CC, Marin F, Ringe JD, Hawkins F, Möricke R, Papaioannu N, Farahmand P, Minisola S, Martínez G, Nolla JM, Niedhart C, Guañabens N, Nuti R, Martín-Mola E, Thomasius F, Kapetanos G, Peña J, Graeff C, Petto H, Sanz B, Reisinger A, Zysset PK. Comparative effects of teriparatide and risedronate in glucocorticoid-induced osteoporosisin men: 18-month results of theEuroGIOPS trial. J Bone Miner Res. 2013 Jan 15. doi: 10.1002/jbmr.1870. [Epub ahead of print)
11. Thomasius F: Correspondence (letter to the editor): S3 guideline was not mentioned. Dtsch Arztebl Int. 2012 Feb;109(5):76-7; reply 77. doi:
12. Bock O, Boerst H, Thomasius FE, Degner C, Stephan-Oelkers M, Valentine SM, Felsenberg D. Common musculoskeletal adverse effects of oral treatment with once weekly alendronate and risedronate in patients with osteoporosis and ways for their prevention. J Musculoskelet Neuronal Interact. 2007 Apr-Jun;7(2):144-8
13. Gluer CC, Eastell R, Reid DM, Felsenberg D, Roux C, Barkmann R, Timm W, Blenk T, Armbrecht G, Stewart A, Clowes J, Thomasius FE, Kolta S. Association of five quantitative ultrasound devices and bone densitometry with osteoporotic vertebral fractures in a population-based sample: the OPUS Study. J Bone Miner Res. 2004 May;19(5):782-93
14. Stepan JJ, Alenfeld F, Boivin G, Feyen JHM, Lakatos P. Mechansims of action of antiresorptive therapies of postmenopausal osteoporosis. Endocr Regl 2003: Vol 37(4): 225-238
15. Alenfeld FE, Engelke K, Schmidt D, Brezger M, Diessel E, Felsenberg D. Diagnostic agreement of two calcaneal ultrasound devices: the Sahara bone sonometer and the Achilles+. Br J Radiol. 2002 Nov;75(899):895-902.
16. Alenfeld FE. Mechansims of action of estrogen on bone. Osteologicky 2002, c.2, 54/55
17. Alenfeld FE, Felsenberg D. HRT und Knochen.: Stellenwert der Hormonersatztherapie in der Prävention und Therapie der osteoporotischen Fraktur. Journal für Menopause; Heft 2/2001
18. Alenfeld FE, Diessel E, Brezger M, Sieper J, Felsenberg D, Braun J. Detailed analyses of periarticular osteoporosis in rheumatoid arthritis. Osteoporos Int. 2000;11(5):400-7.
19. Felsenberg D, Alenfeld F, Bock O, Hammermeister C, Gowan W. Placebo-controlled multicenter study of oral alendronate in postmenopausal osteoporotic. Maturitas. 1998 Nov 30;31(1):35-44.
20. Alenfeld FE, Wuster C, Funck C, Pereira-Lima JF, Fritz T, Meeder PJ, Ziegler R. Ultrasound measurements at the proximal phalanges in healthy women and patients with hip fractures. Osteoporos Int. 1998;8(5):393-8.
21. Alenfeld FE, Bock O, Felsenberg D. Aktuelles zur Therapie der Osteoporose. Der Kassenarzt 1998, 38 (13): 50-57
22. Funck C, Wuster C, Alenfeld FE, Pereira-Lima JF, Fritz T, Meeder PJ, Gotz M, Ziegler R. Ultrasound velocity of the tibia in normal German women and hip fracture patients.. Calcif Tissue Int. 1996 Jun;58(6):390-4.
